ASH 2022 | How to optimize access to CAR-T cell therapies in multiple myeloma
Joshua Richter
• 9 Dec 2022
In this video, Joshua Richter, MD, Mount Sinai Medical Center, New York, NY, discusses strategies to optimize access to CAR-T cell therapies in multiple myeloma (MM), and what treatment approaches to use for patients who progress on T-cell redirecting therapies. This interview took place at the 64th ASH Annual Meeting and Exposition congress in New Orleans, LA.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
Disclosures
Secura Bio: Consultancy, Honoraria; Takeda: Consultancy; Oncopeptides: Consultancy, Honoraria; BMS/Celgene: Consultancy, Honoraria, Membership on an entity’s Board of Directors or advisory committees, Speakers Bureau.
